Shannon earned his Ph.D. from the University of Tennessee, Knoxville in Biochemistry, Cellular and Molecular Biology. His expertise is around T-cell, HSC, and ES/iPSC cell biology, and he has been with Cytiva (formerly GE Healthcare) Cell and Gene Therapy for over 11 years. He is a member of the International Society for Cell Therapy (ISCT) Process and Product Development (PPD) committee, and has authored numerous papers within the field of cell biology and manufacturing. He is currently Cytiva’s Cell and Gene Therapy Enterprise Solutions and FastTrak Leader.
“We are thrilled to have Shannon join our advisory committee” said Haro Hartounian, SVP and general manager of BioCentriq. “The expertise, insights and perspectives he will bring to the table will be much appreciated by our entire team.”
BioCentriq’s advisory committee is made up of a dozen executives from leading pharmaceutical and biotech companies, and is chaired by Dr. Joanne Beck, the chief operating officer of Boston Pharmaceuticals. Peter Marks, the director of the Food and Drug Administration’s Center for Biologics Evaluation and Research is also involved, serving as a liaison to the agency.
Shannon replaces Beth-Thompson Webb who previously served on the advisory committee and has recently joined Aldevron as their Chief Commercial Officer (CCO).